Ultivue

Quickly customize your immune panels with Ultivue’s new innovation

Ultivue’s new multiplex immunofluorescence method optimizes standard anatomic pathology workflows and accelerates assay development

Immune therapy has emerged as the new frontier of cancer treatment.

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized.

The relevance to understand the entire tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells.

The relevance to understand the entire tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells...

Targeting of the programmed cell death protein (PD-1)/ programmed death-ligand 1 (PD-L1) axis with checkpoint inhibitors has changed clinical practice in non-small cell lung cancer (NSCLC).

This webinar will focus on user experiences using the Ultivue InSituPlex fluorescence multiplex IHC platform.